Progression was observed in 13 patients (4 with high-risk MDS and 9 patients with AML) and was associated with the detection of some new recurrent mutations, either occurring alone or in combination: TP53 in 9 cases, TET2 in 6 cases, RUNX1 in 3 cases, PTPN11 and SF3B1 in 1 case [90]. This evidence concerns the gene TET2 and myelodysplastic syndrome.